Errol M. Rudman’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Errol M. Rudman’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30,000	Closed	-$2.55M	–	50
2017 Q4	$2.55M	Hold	30,000	–	–	1.23%	26
2017 Q3	$2.6M	Sell	30,000 -30,000	-50%	-$2.41M	1.49%	21
2017 Q2	$4.63M	Buy	+60,000	New	+$4.26M	2.33%	17

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Errol M. Rudman's XBI Position: Q1 2018 in Review

Errol M. Rudman sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2018, closing a stake of 30,000 shares — an estimated $2.55M sold.

Errol M. Rudman first reported a position in XBI in Q2 2017 and held it in 3 quarters. The position peaked at $4.63M in Q2 2017. 414 funds tracked by Wall St. Rank hold XBI as of Q1 2018.

Errol M. Rudman reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2018 after selling out during the quarter.
Errol M. Rudman sold 30,000 State Street SPDR S&P Biotech ETF shares in Q1 2018, an estimated $2.55M.
Errol M. Rudman first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 3 quarters.
Errol M. Rudman's State Street SPDR S&P Biotech ETF position peaked at $4.63M in Q2 2017.
414 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2018.

Based on Errol M. Rudman's 13F filing for Q1 2018, filed 15 May 2018.